Alprostadil topical - Seelos Therapeutics
Alternative Names: Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Topical ED treatment - Seelos Therapeutics; Virirec; Vitaros; Vytaros; WC-3036Latest Information Update: 05 Nov 2023
At a glance
- Originator NexMed
- Developer Apricus Biosciences; Ferring Pharmaceuticals; Laboratoires Majorelle; Recordati; Seelos Therapeutics
- Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin E1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Erectile dysfunction
- Phase II Raynaud's disease
- Suspended Female sexual dysfunction
- No development reported Premature ejaculation; Wounds
Most Recent Events
- 25 Aug 2020 Launched for Erectile dysfunction in Greece (Topical)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 13 Mar 2019 No recent reports of development identified for preregistration for Erectile dysfunction in Colombia (Topical)